Recently Released Market Study: R&D Trends: Asthma - Extensive Investment in Novel Targets
Datamonitor identified 139 products in development for asthma in 2012. In the near term Datamonitor expects that there will be little change in treatment regimens but strong innovation is seen in earlier stages and Datamonitor expects that novel targeted therapies could make their way through the pipeline, aimed at niche patient groups.
View full press release